


# Pulsar<sup>®</sup>-18 T3

Self-Expanding Stent System

A unique combination  
of 3 technologies




Easy to use, ergonomically  
designed handle.



Tri-axial system  
with braided shaft

**Accurate stent  
deployment**



Low profile delivery system

**Smaller puncture  
site area**

**45%**  
Smaller puncture  
site area vs. 6F<sup>1</sup>



Thin struts, low COF


**Lower risk of  
restenosis<sup>2</sup>**

**89.3%**  
24-m FTLR  
BIOFLEX PEACE<sup>3</sup>


# Pulsar<sup>®</sup>-18 T3

A unique stent with an excellent delivery system


**proBIO<sup>®</sup>**  
coating  
Reduces ion  
release



**140 µm**  
thin struts  
Thinner than  
leading brands



**NEW**  
Additional  
radiopaque marker  
Improved visibility




**NEW**  
Braided  
retractable shaft  
Controlled deployment




Stents up to  
200mm




**Designed for the SFA**  
Multi-directional  
flexibility to conform  
to vessel movement



**Low chronic  
outward force**  
For lower risk  
of restenosis<sup>2</sup>



**NEW**  
Tri-axial shaft  
Accurate stent  
deployment




**4F**  
4F low profile  
45% smaller puncture site  
area vs. 6F<sup>1</sup>



**NEW**  
Wheel operated  
handle  
Easy to use, ergonomically  
designed handle



	A.L.L.	12 months		24 months	
		PP	FTLR	PP	FTLR
<b>ALL-COMERS</b> BIOFLEX PEACE <sup>3</sup> (stent only)	8.2 cm	84.7%	89.3%	78.4%	89.3%
<b>4F INTERVENTIONS</b> 4EVER <sup>4</sup>	7.1 cm	81.4%	89.3%	72.3%	82.7%
<b>LONG &amp; OCCLUDED</b> TASC D <sup>5</sup>	24.5 cm	77.0%	86.0%	-	-



1. BIOTRONIK data on file; 2. Zhao HQ. Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009 Jul;32(4):720-6; 3. Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions – the BIOFLEX PEACE All-Comers Registry. Vasa (2019), 1-9. doi:10.1024/0301-1526a000785. FTLR for stent only group; 4. Bosiers M et al. 4-French – compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive disease: Results of the 4EVER Trial. J ENDOVASC THER. 2013; 20: 746-756; 5. Lichtenberg M et al. Superficial femoral artery TASC D Registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg. 2013;54(4):433-9. Astron Pulsar, Pulsar-18, Pulsar-18 T3 and Pulsar-35 have equivalent stent platforms, therefore the clinical results are valid for the Pulsar range.

COF = Chronic Outward Force; FTLR = Freedom from Target Lesion Revascularization; SFA = Superficial Femoral Artery; A.L.L. = Average Lesion Length (mean ± SD); PP = Primary Patency.

Pulsar and proBIO are trademarks or registered trademarks of the BIOTRONIK Group of Companies.